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Treatment plan comparison in acute and chronic respiratory tract diseases: an 
observational study of doxophylline vs. theophylline  
 
Key issues 
 This is the first attempt in our country to identify two groups of patients who were inquired 
retrospectively and enrolled in the analysis through the respective ATC codes (R03DA04 and 
R03DA11) and develop an administrative cross linkage database in order to estimate 
associated drugs, specialist visits, hospital admissions, plasma drug monitoring in real world 
practice. 
 
 The information system of the pharmaceutical prescriptions allows us to conduct monitoring 
studies of the prescriptions and compare the drugs, taking into account the whole therapeutic 
programme of the patient. However, these prescriptions, by nature, do not allow us to 
identify the therapeutic implications of the administered drugs’ effects. Furthermore, they do 
not allow to compare two groups of completely homogeneous treatment. However, the fact 
that both doxofylline and teophylline have an overlapping RCP allows to assume that the two 
drugs may be equally prescribed. 
 
 Total costs (specific drug, associated drugs including glucocorticoids, specialist visits, plasma 
monitoring of the specific drug, hospital admissions) incurred in the year following the first 
prescription, show a substantial unit cost difference for the patient. The differential is always 
in favour of patients being treated with doxofylline, although the cost of this last drug is 
higher than that of teophylline.). 
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Abstract 
 
Objectives: To estimate the global cost related to the use of the two drugs (associated drugs, 
specialist visits, hospital admissions, plasma drug monitoring). 
Methods: The drug prescriptions were extracted from the Information System of the 
Pharmaceutical Prescriptions of the Marche Region for each ATC code in the years 2008-2012 and 
the number of patients per year and other outcomes measure were obtained.  
Results: 13,574 patients were treated with theophylline and 19,426 patients with doxophylline. 
The number of patients treated was approximately 5,000 per year. Co-prescription with other 
drugs, use of corticosteroids, mean number of visits and  hospital admissions (per 100 patients)  
were lower for doxophylline vs theophylline (1.55vs5.50, 0.3vs0.7, 2.05vs3.73 and 1.57vs3.3 
respectively). The annual mean cost per patient was €187.4  for those treated with doxophylline 
and €513.5 for theophylline. 
Conclusions: In our study, doxophylline resulted to be associated with a reduction of the overall 
cost. 
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 Introduction 
 
Today asthma and COPD (Chronic Obstructive Pulmonary Disorders) represent the second 
disease in the Western world, with a 10% prevalence in the adult population (1) and a growing 
incidence due to both population ageing and environmental pollution (2-5). 
The number of effective drugs that reduce the symptoms and bronchoconstriction 
increased in the last years (6). Among the drugs included in the guidelines of these diseases, 
methylxanthines were an effective tool to reduce the symptoms and prevent bronchoconstriction 
for a long time (7). However, due to the introduction of other drugs, they are now considered 
secondary with respect to other treatments. 
Doxophylline is a second generation methylxanthine, different from theophylline (and 
aminophylline) due to a dioxolane group in the molecule (8). The bronchodilator activity of 
doxophylline was demonstrated in animal studies (9,10) and later in controlled clinical trials 
(11,12) that brought to its registration and launch on the market in the ‘80s. The clinical 
development of doxophylline boosted in the following years, when a series of randomized double-
blind clinical studies was conducted (13). 
However, as the regulation in force when the drug was registered did not require 
randomized double-blind protocols in clinical trials, a Summary of Product Characteristics (SPC) for 
all methylxanthines on the market was approved, concerning overlapping effectiveness, safety and 
precautions. 
The studies conducted on the drug highlighted particular characteristics of doxophylline, 
consisting in bronchodilator effects that basically overlap to those of the main methylxanthines on 
the market (theophylline and aminofylline), with a lower incidence of side effects (14). This 
improved tolerability of the molecule seems to be especially due to a reduced incidence of 
adverse effects on the gastrointestinal (15), cardiovascular (16) and central nervous systems (17). 
These different characteristics brought Page (18) to propose doxophylline as the first of a 
new class of drugs named “Novofyllines”. From a pharmacokinetics point of view, doxophylline 
differs from theophylline for the lack of interferences with cytochromes CYP1A2, CYP2E1, CYP3A4, 
preventing significant interaction with other drugs. The particular tolerance of doxophylline 
justifies the drug’s safety. This is why it is not necessary to proceed to the plasma monitoring of its 
concentration as it occurs with theophylline and aminofylline. These differences with theophylline 
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are not reported on the SPC. Therefore, the prescribing physician who does not refer to literature 
or is not updated, may believe that the two drugs are comparable. 
In light of this, the use of doxophylline (ATC: R03DA11) and theophylline (ATC: R03DA04) in 
an Italian region was analysed, estimating the direct costs of the two treatments in real practice. 
Theophylline has an average base price lower than doxophylline (€4.81 vs €6.37 per prescription). 
 
Methods 
The main flow sources of the Marche region were analysed. The pharmaceutical 
prescriptions for adult patients reported on all the prescriptions sent by municipal and private 
pharmacies of the region, reimbursed by the National Health Service (class A drugs), were 
extracted by the Information System of the Pharmaceutical prescriptions of the Marche Region.  
Through the Marketing Authorization code (AIC) that identifies the active ingredient (ATC code - 
Anatomical-Therapeutic-Chemical Classification) it was possible to find the patients to whom the 
concerned drugs were administered. In the specific database for each prescription the date of 
drug administration and the patient’s personal information were reported and made anonymous 
by means of a unique code. 
The analysis identified two groups of patients who were inquired retrospectively and 
enrolled in the analysis through the respective ATC codes (R03DA04 and R03DA11). Through this 
selection the number of prescriptions made over the period 1 January 2008 and 31 December 
2012 was estimated. Later it was possible to trace back the number of “users”. 
The yearly number of prescriptions was obtained selecting all the prescriptions by single 
active ingredient prescribed in the monitoring period. The number of users was estimated 
identifying the subjects who received at least one prescription of ATC in the trial period.  
To estimate the days of treatment 5 days of treatment with syrup (AIC 011226091 for 
theophylline and AIC 025474065 and 033887047 for doxophylline) were assumed, together with 
10 days of treatment with tablets (all the other AICs). 
Furthermore, the drugs that could be associated with enrolment ATCs and that were part 
of the asthma therapy were identified. The concomitant prescriptions were estimated selecting all 
the ATC prescriptions that were identified as potentially associated with the following main active 
ingredients being studied: 
R03AC (selective agonists of the beta-2 adrenergic receptors), R03AK (adrenergics and other drugs 
for obstructive respiratory syndromes), R03BA (glucocorticoids), R03BB (anticholinergics), R03CC 
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(selective agonists of beta-2 adrenergic receptors) and R03DC (antagonists of leukotrienes 
receptors). 
Through a record linkage procedure, the identified prescriptions were associated with 
previously extracted prescriptions for theophylline and doxophylline, through the anonymous 
code identifying the user. 
To define the “concomitant therapy” an interval of ±30 days was identified from the 
prescription of theophylline or doxophylline and a prescription of one of the associated active 
ingredients. 
As far as the prescription price is concerned, the “price” information contained in the 
prescription record was used, without taking into account the information related to the amount 
to be paid by the patient. 
The linkage to the patient also allowed to identify the hospital admissions of each 
therapeutic group. Specifically, the hospital admissions that were registered in the hospital 
register over the period 2008-2012, within the calendar year from the first prescription observed, 
were taken into account. The hospital admissions considered in this analysis had to be associated 
with asthma or COPD or possible adverse events related to the treatment, identifying the DRGs 
reported in note 1. 
Also in this case the calculation was made at reimbursement rates associated with the DRG 
required by NHS and included in the regional database. 
Finally, the specialist visits potentially associated with the patients under therapy included 
in the analysis were considered. In particular, the codes reported in the range of fees indicated in 
note 2 were selected. 
Through the anonymous linking code, total and average costs per patient treated with each 
type of treatment were estimated. In particular, the costs were broken down by: drug cost 
(doxophylline and theophylline), cost of associated drugs, cost of glucocorticoids (ATC R03BA), 
cost of monitoring with theophyllinemia (cod. 90.41.2), cost of other specialist visits. 
For each subject, clinical history was defined by retrieving specific conditions recorded 
during hospitalizations in the two years previous the first prescription. The conditions analysed 
were: cancer, diabetes, lipid metabolism disturbances, obesity, blood disorders, hypertension, 
thyroid gland disorders, ischemic diseases, heart failure, chronic pulmonary heart disease, 
neurological and muscular diseases, systemic diseases, digestive system diseases, other heart 
conditions, conduction disturbances and arrhythmias, cerebrovascular disease, mental and 
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psychiatric disorders, acute chronic respiratory conditions, chronic respiratory diseases, chronic 
renal disease (ICD9CM codes in appendix). 
The association between drugs and concomitant therapy, hospitalizations, and specialist 
visits were studied using Poisson regression models [Risk Ratio (RR)] adjusting for age, sex and risk 
factors. A stepwise bootstrap procedure was adopted in order to select statistically significant 
confounding variables. 
Concomitant therapy was defined as one prescription of the associated active ingredients 
within 30 days after first prescription of theophylline or doxophylline. 
Regarding hospitalization admissions, it was considered all hospitalizations within 1 year 
from first drug prescription. Specialist visits were defined as the visits within 60 days from first 
prescription. 
The analysis of costs was performed stratifying for age and sex.  
Differences between two treatment groups were tested using t-test for continuous 
variables and χ2 test for categorical variable and a p-value lower than 0.05 was considered 
statistically significant. 
Results 
In the Marche region out of 1,555,560 patients were treated with drugs in the analysed 
period (mean of resident population in 2008-2013; source Istat). On the basis of xanthine 
prescription, 32,998 people were suspected of being affected from asthma and COPD. 
Based on the heterogeneity of the patients being treated in the two groups of drugs, the 
results are reported below: 
 
1. Total population considered based on the prescription of the two drugs 
As reported in table 1, 13,574 patients being treated with theophylline who received 94,454 
prescriptions and 19,424 patients being treated with doxophylline who received 62,791 
prescriptions were identified. 
Both drugs were mainly used in the elderly population. However, the percentage of use is 
higher for doxophylline up to 75 years of age and reverses in the older population (Figure 1). The 
mean age for theophylline is 73 years, while for doxophylline is 67 (t-test p<0.001). Analysing the 
distribution by sex (Figure 2) it may be observed that doxophylline is more prescribed in the 
female population in both age segments. 
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2. Co-prescriptions associated with the two drugs 
In the total population of patients treated with methylxanthines, the risk of co-prescription was 
lower for patient treated with doxophylline compared with theophylline (RRadj 0.84; 95% CI 
0.78-0.90). 
The average number of co-prescriptions per patient is equal to 5.50 for theophylline and 1.55 for 
doxophylline, with a 71.7% reduction of co-prescriptions (Figure 3). 
Considering that polypharmacotherapy prevails in the elderly population (over 65), in the 
population treated with methylxanthines the average number of co-prescriptions per patient is 
6.07 for theophylline and 2.06 for doxophylline, with a reduction of co-prescriptions of 66.0%. 
In polypharmacotherapy, the average number of co-prescriptions for female patients in the elderly 
population is 4.05 for theophylline and 1.39 for doxophylline, with a 65.6% reduction of co-
prescriptions. In male patients versus female ones of the same age, a 93% increase of average 
prescription per patient for theophylline (7.82 average co-prescriptions per patient) and 102.9% 
for doxophylline (2.83 average co-prescriptions per patient) was observed. 
The guidelines indicate the possibility to use glucocorticoids in the asthma or COPD treatment. 
However, given the scientific evidence of an anti-inflammatory activity of doxophylline (13), the 
prescription associated with glucocorticoids was analysed in detail. 
As far as the co-prescriptions are concerned, it was observed that the association with 
glucocorticoids is always higher with theophylline (0.7 average co-prescriptions per patient) with 
respect to doxophylline (0.3 average co-prescriptions per patient) (Figure 3). 
The difference of average co-prescription of glucocorticoids per patient in the male population is  
higher (0.9 and 0.3 prescriptions) than in the female population (0.6 and 0.3). 
Considering that these drugs are mainly prescribed in the elderly population, this association was 
further analysed in patients aged over 65. In the elderly population, the co-prescription of 
glucocorticoids is 0.8 average co-prescriptions per patient for theophylline and 0.3 average co-
prescriptions per patient for doxophylline: -58.1% (Figure 3). 
Again, a gender-specific difference in the average co-prescription of glucocorticoids per patient in 
patients aged over 65, both associated with theophylline (1.0 in men and 0.6 in women) and 
doxophylline (0.4 in men and 0.3 in women) may be observed. 
Comparing the genders, the co-prescription of glucocorticoids was always lower in women both 
with theophylline and doxophylline. 
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3. Specialist services associated with the treatment with theophylline or doxophylline 
For each treated patient the average number of services associated with theophylline (Note2; 
figure 3)  was 3.73 for theophylline and 2.05 for doxophylline (RRadj 0.90, 95% CI 0.85-0.94). 
In the elderly population these services per treated patient increase to 4.18 for theophylline and 
2.52 for doxophylline. 
Again, a gender-specific difference between males (4.43 for theophylline and 2.38 for 
doxophylline) and females (2.95 for theophylline and 1.75 for doxophylline) was observed.  
As during the therapy with theophylline a periodical check of its plasma concentration is 
recommended –although this therapy is considered “obsolete” and therefore not always used- it 
was inquired whether it was used during the therapy with the two xanthines. As it may be 
observed, the number of theophyllinemies per 100 patients was negligible for a therapy with 
doxophylline (figure 3). 
 
4. Hospital admissions associated with the treatment with theophylline or doxophylline 
The number of DRG-specific hospital admissions for asthma and COPD observed during both 
therapies was extremely low: 1.2/100 patients treated with theophyllineand 0.6/100 patients 
treated with doxophylline. The risk of hospitalization within 1 year from first prescription was 
lower in patients treated with doxophylline compared with theophylline, but not statistically 
significant (RRadj 0.94, 95% CI 0.75-1.17). 
There were no significant differences between the population over 65 and the total one in 
patients treated with doxophylline (0.5/100 patient, t-test p-value 0.173), while hospitalization 
rate in patients over 65 treated with theophylline reduced to 0.6/100 (t-test p<0.001). DRG-
specific hospital admissions had a significant gender differential: the number of hospital 
admissions was 0.3/100 for male patients treated with theophylline and 3.7/100 for female 
patients (t-test p<0.001); the number of hospital admissions was 0.2/100 for male patients treated 
with doxophylline and 1.7/100 for female patients (t-test p<0.001). 
Reducing the period of observation associated with the prescription of methylxanthines (±5 days), 
the results of previous analyses were unchanged (data are not reported). 
 
5. Costs associated with the treatment with theophylline or doxophylline 
Considering the services associated with the treatment within ±30 days, a net cost difference in 
the total population was observed, with an average yearly cost of €513.6 per patient treated with 
10 
theophylline, versus €187.4 per patient treated with doxophylline (Figure 4). Obviously, in the 
elderly population (over 65) a higher cost than that of younger population under treatment with 
both drugs was observed. However, once again the therapy cost with doxophylline (€247.7 per 
patient) was definitely lower than that with theophylline (€577.3 per patient) (Figure 4). 
 
Discussion 
The information system of the pharmaceutical prescriptions allows us to conduct 
monitoring studies of the prescriptions and compare the drugs, taking into account the whole 
therapeutic programme of the patient. However, these prescriptions, by nature, do not allow us to 
identify the therapeutic implications of the administered drugs’ effects. Furthermore, they do not 
allow to compare two groups of completely homogeneous treatment. However, the fact that both 
doxophylline and theophylline have an overlapping RCP allows to assume that the two drugs may 
be equally prescribed. 
In the population of the Marche Region, during the considered five-year period (2008-
2012), the number of patients treated with theophylline was lower than that of patients treated 
with doxophylline. However, the number of theophylline prescriptions was higher than that of 
doxophylline. This demonstrates that although methylxanthines are obsolescent in the market, the 
physicians still consider them a valid tool to monitor respiratory disease symptoms. 
The prescription of theophylline resulted always higher than that of doxophylline in males. 
Conversely, this did not occur in females, regardless the age segment considered. 
The analysis of the association of the two methylxanthines with other drugs highlighted an 
average number of co-prescriptions per patient definitely higher for theophylline both by sex and 
age segment. It is observed that when the two methylxanthines are associated with 
glucocorticoids, these drugs are less necessary when doxophylline is used. This difference is 
significant both in terms of the average number of treated patients in the whole population (0.3 
for doxophylline versus 0.7 for theophylline) and only taking into account the prescription in the 
over 65 age segment (0.3 for doxophylline versus 0.8 for theophylline; -58.1% of prescriptions). 
Finally, considering this age segment, it is observed that doxophylline seems to require a higher 
reduction of glucocorticoids both in men (0.4 for doxophylline versus 1.0 for theophylline) and 
women (0.3 for doxophylline versus 0.6 for theophylline). 
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This reduced need to indirectly co-prescribe glucocorticoids seems to confirm the anti-
inflammatory activity associated with doxophylline in the human being, as demonstrated by Page 
in vivo (18). This consumption data is important considering that doxophylline is mainly prescribed 
to women who experience the highest osteoporosis damage after the corticosteroid therapy 
(19,20).  
The recourse to specialist consultations during the therapy with theophylline was higher both in 
the total population and the elderly one. Such difference confirms a higher sense of safety in the 
use of doxophylline by both the physician and the patient. This seems to be confirmed by the fact 
that although women were prescribed more doxophylline, they were submitted less to specialist 
consultations. Furthermore, the assumption of a higher safety of doxophylline is confirmed by the 
fact that the patients being treated with it were detected a negligible plasma drug concentration 
in periodical checks. 
The warning contained in the technical data sheet of this drug recommends a monitoring 
of its plasma concentration in case there are factors affecting its clearance.  
The hospital admissions of the population observed in the group of patients treated with 
theophylline are higher both when specific DRG (asthma and COPD: 1.2 vs 0.6 for theophylline and 
doxophylline respectively) were considered and when all possible DRGs related to potential 
adverse events (1.9 vs 1.0; theophylline vs doxophylline) were taken into account. No difference 
was observed when the patient age was considered. In female patients who received the highest 
number of doxophylline prescriptions, the number of hospital admissions was definitely lower (1.7 
vs 3.7 for doxophylline and theophylline respectively). 
Finally, total costs (specific drug, associated drugs including glucocorticoids, specialist visits, 
plasma monitoring of the specific drug, hospital admissions) incurred in the year following the first 
prescription, show a substantial unit cost difference for the patient. The differential is always in 
favour of patients being treated with doxophylline, although the cost of this last drug is higher 
than that of theophylline. 
This study shows an important limit that should be taken into account. The administrative data do 
not allow us to know the patient’s health state (including concomitant diseases) and the treated 
disease (asthma and COPD) at the time of the first prescription. Therefore, there are two possible 
biases in the patients’ treatment. 
  The first bias could be given by the physician belief that theophylline is more effective than 
doxophylline. Consequently, the more severe patients were treated with this drug. 
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This hypothesis could be confirmed by the fact that theophylline treated patients had higher 
coprescriptions, visits and hospital admissions. The coprescriptions were needed even in presence 
of potential higher risk of drug interactions and adverse reactions.  
  The second bias may be due to the prescriber’s belief that doxophylline is safer. Therefore, it was 
the drug to be prescribed to the more severe patients. The lack of necessity to therapeutic drug 
monitoring of doxophylline could be more “accepted” by the patient and certainly less “worrying” 
for the prescriber. The anti-inflammatory activity of doxophylline and the reduced needed of the 
glucocorticoid association could explain the lower number of coprescriptions as well as the less 
number of visits and hospital admissions. 
Unfortunately administrative data, which do not allow us to know the patient’s history at the time 
of first prescription, make both hypothesis possible. 
--Finally, a third hypothesis should be taken into account. Since the technical data sheets of the 
two drugs are identical, it is highly possible that the physicians indistinctly chose theophylline or 
doxophylline, because they have the same profile of activity (7,10-13,18,21-24).  
 In conclusion, this analysis undoubtedly demonstrates a significant difference in the unit 
cost per patient in favour of doxophylline.  Although the drug cost is higher, prescribers are 
recommended to prescribe it instead of theophylline, not only for its higher tolerance and 
manageability, but also because it reduces the costs associated with COPD and/or asthma 
treatments.  
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Appendix 
Note 1. DRGs potentially associated with asthma and/or COPD or to possible adverse events 
(cardiovascular, gastrointestinal and neurological events) of the drug. 
- DRG 96 (Bronchitis and asthma, age >17 with CC) 
- DRG 97 (Bronchitis and asthma, age >17 without CC) 
- DRG 98 (Bronchitis and asthma, age <18) 
- DRG 99 (Respiratory signs and symptoms with CC) 
- DRG 100 (Respiratory signs and symptoms without CC) 
- DRG138 (arrhythmia and cardiac conduction alteration with CC) 
- DRG139 (arrhythmia and cardiac conduction alteration without CC) 
- DRG174 (Gastrointestinal bleeding with CC) 
- DRG182 (oesophagitis, gastroenteritis and miscellaneous of digestive system disorders, age 
>17 with CC) 
- DRG183 (oesophagitis, gastroenteritis and miscellaneous of digestive system disorders, age 
>17 without CC) 
- DRG175 (gastrointestinal bleeding without CC) 
- DRG024 (convulsions and cephalalgia, age >17 with CC) 
- DRG025 (convulsions and cephalalgia, age > 17 no CC) 
- DRG564 (cephalalgia, age >17) 
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Note 2. Codes of tariffs in the range of fees for specialist visits potentially associated with 
therapies being analysed 
- 33.22 (bronchoscopy with optical fibres) 
- 34.24 (bronchial biopsy [endoscopic]) 
- 38.98.1 (contrast medium injection for radiotherapic simulation TC) 
- 38.99.2 (contrast medium injection for radiotherapic simulation RM) 
- 45.13 (esophagogastroduodenoscopy [EGD]) 
- 87.41 (chest [CT] scan)  
- 87.44.1 (routine chest x-ray, NAS) 
- 89.03 (medical history and evaluation, defined overall) 
- 89.07 (consultation, defined overall) 
- 89.13 (neurological examination) 
- 89.37.1 (simple spirometry) 
- 89.37.2 (global spirometry) 
- 89.37.4 (pharmacological bronchodilator test) 
- 89.37.5 (bronchodynamic test with specific and non-specific bronchoconstrictor) 
- 89.37.6 (bronchodynamic test with specific bronchoconstrictor) 
- 89.38.1 (airway resistance) 
- 89.38.2 (global spirometry with plethysmography) 
- 89.38.3 (alveolar-capillary diffusion of CO2) 
- 89.38.4 (static and dynamic pulmonary compliance) 
- 89.38.5 (breathing pattern at rest) 
- 89.38.6 (evaluation of ventilation and expired gases and related parameters) 
- 89.38.7 (maximum inspiratory and expiratory pressure) 
- 89.38.8 (ventilation distribution test with non-radioactive gases) 
- 89.38.9 (PO.1 determination) 
- 89.41 (cardiovascular stress test with mobile springboard) 
- 89.43 (cardiovascular stress test with bicycle ergometer) 
- 89.44.1 (cardiorespiratory stress test) 
- 89.44.2 (walk test) 
- 89.50 (dynamic electrocardiogram) 
- 89.52 (electrocardiogram) 
- 89.54 (electrocardiographic monitoring) 
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- 89.61.1 (24 hour monitoring of blood pressure) 
- 89.65.1 (systemic arterial blood gas test) 
- 89.65.2 (blood gas test during high-concentration O2 respiration) 
- 89.65.3 (blood gas test during low-concentration O2 respiration) 
- 89.65.4 (O2 and CO2 transcutaneous monitoring) 
- 89.65.5 (non invasive monitoring of arterial saturation) 
- 89.65.6 (blood gas test before and after hyperventilation) 
- 89.7 (general examination) 
 
Note 3. ICD 9 CM Codes of conditions considered in risk adjustment procedure 
CONDITION ICD 9CM CODES 
Cancer 140.0–208.9, V10 
Diabetes  250.0-250.9  
Lipid metabolism disturbances  272 
Obesity  278.0 
Blood disorders  280, 281, 285.9, 286, 287.1, 287.3-287.5 
Hypertension  401-405 
thyroid gland disorders 240-245 (excl. 245.0 245.1) 246 
Ischemic diseases  410-414 414, 429.7 
Heart failure and Chronic pulmonary heart disease  428, 416.9 
Neurological and muscular diseases 331, 332, 333.4, 333.5, 334-335, 336.2, 
340, 341, 342, 343, 344, 345, 348.1, 348.3, 
356, 358, 359, 784.3 
Systemic diseases 446, 701.0, 710, 711.2, 714, 719.3, 720, 
725 
Digestive system diseases 456.0- 456.2, 571-572 (excl. 571.1, 572.0- 
572.2), 573.0, V42.7, 577.1-577.9, 555, 
556 
Other heart conditions  093.2, 391, 393-398, 420-425, 429 
(excl.429.7), 745, 746.3-746.6, V15.1, 
V42.2, V43.2, V43.3, V45.0, V45.81, V45.82 
procedures: 00.66, 35, 36.1, 36.0,37.0, 
37.1, 37.3, 37.4,37.5, 37.6, 37.9 
Conduction disturbances and arrhythmias  426.0, 426.10, 426.12, 426.13, 426.7, 
426.9, 427, 785.0, 996.01, 996.04, V45.0, 
V53.3 
Cerebrovascular disease  
430-438,  440-448, 557, 093.0 
procedures: 38.01, 38.02, 38.11, 38.12, 
38.31, 38.32, 38.41, 38.42, 38.61, 38.62, 
38.81, 38.82, 38.08, 38.18, 38.38, 38.48, 
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CONDITION ICD 9CM CODES 
38.68, 38.88, 39.29, 38.04-38.07, 38.14-
38.16, 38.34-38.37, 38.44-38.47, 38.55, 
38.57, 38.64-38.67, 38.7, 38.84-38.87, 
30.0, 39.1, 39.21-39.26, 39.52, 39.54 
Mental and psychiatric disorders 
293.8, 295-298, 299.1, 300.4, 301.12, 
309.0, 309.1, 311, 290.0-290.4, 294.1, 
331.0 
Acute chronic respiratory conditions 
518.81, 518.82, 786.0, 512, 518.0, 415, 
466.0, 480-486, 487.0, 510, 511, 513, 011, 
012.0, 012.1, 012.2, 012.8 
Chronic respiratory diseases  
493, 495, 135, 500-505, 506-508, 515, 516, 
517, 518.1-518.3, 518.89, 519 
Chronic renal disease  
582-583, 585-588, V42.0, V45.1, V56 
procedures 38.95, 39.95, 54.98 
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Tables and Figures 
 
Table 1 – ANALYSED SAMPLE 
ATC Year Patients Prescriptions Boxes 
Theophylline 
2008 6,258 24,893 39,214 
2009 5,473 21,928 34,643 
2010 4,502 18,283 29,049 
2011 3,954 15,797 24,986 
2012 3,376 13,553 21,558 
Total 2008-2012 13,574 94,454 149,450 
Doxophylline 
2008 6,278 14,639 21,753 
2009 6,218 14,112 20,631 
2010 5,615 12,825 18,443 
2011 5,123 11,373 16,340 
2012 4,289 9,842 14,233 
Total 2008-2012 19,424 62,791 91,400 
 
 
 
 
 
Figure 1. Percentage of use (by age segment) of doxophylline and theophylline 
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A. Total population 
 
 
B. Patients over 65 
 
 
Figure 2. Distribution by sex according to the treatment (A. Total population; B. Patients over 
65) – Marche Region 2008-2012 
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A. Number of services (total population) 
 
B. Number of services (over 65) 
 
Figure 3. Services associated with treatment with the two drugs (A. Total population; B. Patients 
over 65) – Marche Region 2008-2012 
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A. Average yearly cost for associations ±30 days (total population) 
 
A. Average yearly cost for associations ±30 days (over 65) 
 
 
Figure 4. Average yearly cost for associations ±30 days (A. Total population; B. Over 65 patients) 
Marche Region 2008-2012 
 
 
